Nancy joined Kallyope as Chief Executive Officer at the company’s launch in November 2016. She was formerly Senior Vice President and Franchise Head, Diabetes and Endocrinology, Merck & Co. Inc. In this role she led discovery and clinical research in diabetes, osteoporosis, fertility and contraception. Prior to her role as Franchise Head, Nancy initiated and was a leader of Merck’s dipeptidyl peptidase 4 (DPP-4) project, which resulted in the discovery of JANUVIA® for the treatment of Type 2 diabetes. Among other notable scientific accomplishments is the identification of the first caspase, interleukin-1β converting enzyme (ICE/caspase-1). For her scientific contributions she has received numerous awards, including the Merck Presidential Fellowship, Merck Directors Award, Heroes of Chemistry Award by the American Chemical Society, and in 2011 received the Pharmaceuticals Research and Manufacturers of America (PhRMA) Discoverers Award, which honors research scientists whose work has been of special benefit to humankind. In addition to her role at Kallyope, she serves as a Director at Intarcia Therapeutics.